BeiGene, Ltd. (BGNE)
| Previous Close | 131.67 |
| Open | 139.00 |
| Bid | 127.70 x 900 |
| Ask | 188.50 x 900 |
| Day's Range | 129.30 - 139.45 |
| 52 Week Range | 120.00 - 426.56 |
| Volume | |
| Avg. Volume | 351,831 |
| Market Cap | 14.588B |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.17 |
| Earnings Date | Aug 07, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 421.58 |
- Business Wire
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 17, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company’s operations in the region.
- Business Wire
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
CAMBRIDGE, Mass., BEIJING & BASEL, Switzerland, May 12, 2022--BeiGene announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at EHA.
- Simply Wall St.
Despite currently being unprofitable, BeiGene (NASDAQ:BGNE) has delivered a 304% return to shareholders over 5 years
BeiGene, Ltd. ( NASDAQ:BGNE ) shareholders might understandably be very concerned that the share price has dropped 33...
